TISIDB

Summary
Symbol	ACTA2
Name	actin, alpha 2, smooth muscle, aorta
Aliases	ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location	10q23.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytoskeleton.
Domain	PF00022 Actin
Function	Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0001655 urogenital system development GO:0001822 kidney development GO:0002064 epithelial cell development GO:0003012 muscle system process GO:0003013 circulatory system process GO:0003018 vascular process in circulatory system GO:0006936 muscle contraction GO:0006939 smooth muscle contraction GO:0008015 blood circulation GO:0008217 regulation of blood pressure GO:0009615 response to virus GO:0014829 vascular smooth muscle contraction GO:0032835 glomerulus development GO:0035150 regulation of tube size GO:0035850 epithelial cell differentiation involved in kidney development GO:0042310 vasoconstriction GO:0050880 regulation of blood vessel size GO:0060485 mesenchyme development GO:0061005 cell differentiation involved in kidney development GO:0061437 renal system vasculature development GO:0061440 kidney vasculature development GO:0061448 connective tissue development GO:0072001 renal system development GO:0072006 nephron development GO:0072007 mesangial cell differentiation GO:0072008 glomerular mesangial cell differentiation GO:0072012 glomerulus vasculature development GO:0072109 glomerular mesangium development GO:0072132 mesenchyme morphogenesis GO:0072143 mesangial cell development GO:0072144 glomerular mesangial cell development GO:0090066 regulation of anatomical structure size GO:0090130 tissue migration GO:0090131 mesenchyme migration GO:1904238 pericyte cell differentiation
Molecular Function	-
Cellular Component	GO:0015629 actin cytoskeleton GO:0030027 lamellipodium GO:0030175 filopodium GO:0030485 smooth muscle contractile fiber GO:0031252 cell leading edge GO:0043292 contractile fiber GO:0044297 cell body GO:0044449 contractile fiber part GO:0098858 actin-based cell projection

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04270 Vascular smooth muscle contraction
Reactome	R-HSA-397014: Muscle contraction R-HSA-445355: Smooth Muscle Contraction

Summary
Symbol	ACTA2
Name	actin, alpha 2, smooth muscle, aorta
Aliases	ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location	10q23.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ACTA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ACTA2
Name	actin, alpha 2, smooth muscle, aorta
Aliases	ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location	10q23.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ACTA2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ACTA2
Name	actin, alpha 2, smooth muscle, aorta
Aliases	ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location	10q23.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ACTA2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.969	0.0392
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.285	0.666
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.734	0.732
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.522	0.521
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.709	0.819
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.28	0.945
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.246	0.635
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.016	0.993
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.486	0.817
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.192	0.681
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.489	0.553
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.467	0.0124

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ACTA2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	ACTA2
Name	actin, alpha 2, smooth muscle, aorta
Aliases	ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location	10q23.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACTA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ACTA2
Name	actin, alpha 2, smooth muscle, aorta
Aliases	ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location	10q23.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACTA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACTA2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ACTA2
Name	actin, alpha 2, smooth muscle, aorta
Aliases	ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location	10q23.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACTA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ACTA2
Name	actin, alpha 2, smooth muscle, aorta
Aliases	ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location	10q23.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ACTA2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ACTA2
Name	actin, alpha 2, smooth muscle, aorta
Aliases	ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location	10q23.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ACTA2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ACTA2
Name	actin, alpha 2, smooth muscle, aorta
Aliases	ACTSA; AAT6; MYMY5; cell growth-inhibiting gene 46 protein; Alpha-actin-2; Actin, aortic smooth muscle
Chromosomal Location	10q23.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ACTA2 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ACTA2.

ID	Name	Drug Type	Targets	#Targets
DB12695	Phenethyl Isothiocyanate	Small Molecule	ACTA2, ACTB, ATP5B, ATP5I, ATP5L, CYB5B, DIABLO, FBXO41, HNRNPF, H ......	45

Browse ACTA2